Joseph Grudzinski
Overview
Explore the profile of Joseph Grudzinski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khan J, Ryden T, Van Essen M, Svensson J, Grudzinski J, Bernhardt P
EJNMMI Phys
. 2024 Aug;
11(1):71.
PMID: 39090481
Introduction: This study aims to evaluate the use of CT-based whole kidney parenchyma (WKP) segmentation in Lu-DOTATATE dosimetry. Specifically, it investigates whether WKP volumes change during treatment and evaluates the...
2.
Marsh I, Li C, Grudzinski J, Jeffery J, Longhurst C, Adam D, et al.
Cancer Biother Radiopharm
. 2023 Apr;
38(7):458-467.
PMID: 37022739
Delivery of radiotherapeutic dose to recurrent head and neck cancer (HNC) is primarily limited by locoregional toxicity in conventional radiotherapy. As such, HNC patients stand to benefit from the conformal...
3.
Carlson P, Patel R, Birstler J, Rodriquez M, Sun C, Erbe A, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36639155
Background: The antitumor effects of external beam radiation therapy (EBRT) are mediated, in part, by an immune response. We have reported that a single fraction of 12 Gy EBRT combined...
4.
Potluri H, Ferreira C, Grudzinski J, Massey C, Aluicio-Sarduy E, Engle J, et al.
J Immunother Cancer
. 2022 Aug;
10(8).
PMID: 36002185
Background: Systemic radiation treatments that preferentially irradiate cancer cells over normal tissue, known as targeted radionuclide therapy (TRT), have shown significant potential for treating metastatic prostate cancer. Preclinical studies have...
5.
Magee K, Marsh I, Turek M, Grudzinski J, Aluicio-Sarduy E, Engle J, et al.
PLoS One
. 2021 Aug;
16(8):e0255798.
PMID: 34383787
Rationale: Murine syngeneic tumor models have revealed efficacious systemic antitumor responses following primary tumor in situ vaccination combined with targeted radionuclide therapy to secondary or metastatic tumors. Here we present...
6.
Patel R, Hernandez R, Carlson P, Grudzinski J, Bates A, Jagodinsky J, et al.
Sci Transl Med
. 2021 Jul;
13(602).
PMID: 34261797
Molecular and cellular effects of radiotherapy on tumor microenvironment (TME) can help prime and propagate antitumor immunity. We hypothesized that delivering radiation to all tumor sites could augment response to...
7.
Xiao Y, Roncali E, Hobbs R, James S, Bednarz B, Benedict S, et al.
Int J Radiat Oncol Biol Phys
. 2021 Feb;
109(4):902-904.
PMID: 33610302
No abstract available.
8.
Roncali E, Capala J, Benedict S, Akabani G, Bednarz B, Bhadrasain V, et al.
J Nucl Med
. 2020 Dec;
62(8):1133-1139.
PMID: 33277396
In 2018, the National Cancer Institute and NRG Oncology partnered for the first time to host a joint workshop on systemic radiopharmaceutical therapy (RPT) to specifically address dosimetry issues and...
9.
James S, Bednarz B, Benedict S, Buchsbaum J, Dewaraja Y, Frey E, et al.
Int J Radiat Oncol Biol Phys
. 2020 Aug;
109(4):891-901.
PMID: 32805300
In radiopharmaceutical therapy (RPT), a radionuclide is systemically or locally delivered with the goal of targeting and delivering radiation to cancer cells while minimizing radiation exposure to untargeted cells. Examples...
10.
Marsh I, Grudzinski J, Baiu D, Besemer A, Hernandez R, Jeffery J, et al.
J Nucl Med
. 2019 Mar;
60(10):1414-1420.
PMID: 30926646
Cancer is the second leading cause of death for children between the ages of 5 and 14 y. For children diagnosed with metastatic or recurrent solid tumors, for which the...